ArticleAntimicrobial agents and chemotherapy2012
Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 71 citations in OpenAlex.
- Component A2 is a redox-sensitive archaeal ATPase activated by methyl-coenzyme M reductase.Current biology : CB · 2026Article
- Discovery of the Phosphonate Flavophos Produced byJournal of the American Chemical Society · 2026Article
- Component A2 is a redox-sensitive archaeal ATPase activated by methyl-coenzyme M reductase.bioRxiv : the preprint server for biology · 2026Article
- Discovery of the Phosphonate Flavophos Produced bybioRxiv : the preprint server for biology · 2026Article
- Methanogenic archaea encoding Pyrrolysine maintain ambiguous amber codon usage.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Methanogenesis marker 16 metalloprotein is the primary coenzyme M synthase in Methanosarcina acetivorans.PLoS genetics · 2025Article
- Complete Biochemical Characterization of Pantaphos Biosynthesis Highlights an Unusual Role for a SAM-Dependent Methyltransferase.Angewandte Chemie (International ed. in English) · 2024Article
- Convergent and divergent biosynthetic strategies towards phosphonic acid natural products.Current opinion in chemical biology · 2022Review
- Biosynthesis of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis.Applied and environmental microbiology · 2022Article
- An Archaea-specificeLife · 2022Article
- Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa andAntimicrobial agents and chemotherapy · 2022Review
- Beyond Soil-Dwelling Actinobacteria: Fantastic Antibiotics and Where to Find Them.Antibiotics (Basel, Switzerland) · 2022Review
- An inventory of early branch points in microbial phosphonate biosynthesis.Microbial genomics · 2022Article
- Article
- Biosynthesis of fosfomycin in pseudomonads reveals an unexpected enzymatic activity in the metallohydrolase superfamily.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Overall Retention of Methyl Stereochemistry during BBiochemistry · 2021Article
- Cryptic or Silent? The Known Unknowns, Unknown Knowns, and Unknown Unknowns of Secondary Metabolism.mBio · 2020Article
- Functional interactions between posttranslationally modified amino acids of methyl-coenzyme M reductase in Methanosarcina acetivorans.PLoS biology · 2020Article
- The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic.RSC advances · 2019Review
- GDGT cyclization proteins identify the dominant archaeal sources of tetraether lipids in the ocean.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Fosfomycin is a wide-spectrum antibiotic that is used clinically to treat acute cystitis in the United States. The compound is produced by several strains of streptomycetes and pseudomonads. We sequenced the biosynthetic gene cluster responsible for fosfomycin production in Pseudomonas syringae PB-5123. Surprisingly, the biosynthetic pathway in this organism is very different from that in Streptomyces fradiae and Streptomyces wedmorensis. The pathways share the first and last steps, involving conversion of phosphoenolpyruvate to phosphonopyruvate (PnPy) and 2-hydroxypropylphosphonate (2-HPP) to fosfomycin, respectively, but the enzymes converting PnPy to 2-HPP are different. The genome of P. syringae PB-5123 lacks a gene encoding the PnPy decarboxylase found in the Streptomyces strains. Instead, it contains a gene coding for a citrate synthase-like enzyme, Psf2, homologous to the proteins that add an acetyl group to PnPy in the biosynthesis of FR-900098 and phosphinothricin. Heterologous expression and purification of Psf2 followed by activity assays confirmed the proposed activity of Psf2. Furthermore, heterologous production of fosfomycin in Pseudomonas aeruginosa from a fosmid encoding the fosfomycin biosynthetic cluster from P. syringae PB-5123 confirmed that the gene cluster is functional. Therefore, two different pathways have evolved to produce this highly potent antimicrobial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.